Skip to search formSkip to main contentSkip to account menu

ZD 1839

Known as: ZD1839 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

gefitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Purpose: Epidermal growth factor receptor (EGFR) signal transduction pathways are implicated in malignant glioma aggressiveness… 
Highly Cited
2004
Highly Cited
2004
Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth…
Purpose: The purpose of this research was to assess the effects of single agent and combination treatment with trastuzumab and… 
Highly Cited
2004
Highly Cited
2004
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Purpose: A worldwide compassionate-use program has enabled >42,000 patients with advanced non-small cell lung cancer (NSCLC) to… 
Review
2004
Review
2004
Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Lung cancer is the leading cause of death worldwide. Current treatment modalities, including chemotherapy, radiotherapy and… 
Review
2003
Review
2003
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Epidermal growth factor receptor (EGFR) is commonly overexpressed in a number of epithelial malignancies and is often associated… 
Highly Cited
2003
Highly Cited
2003
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Whether the apparent efficacy of a specific kinase inhibitor is attributable solely to inhibition of its primary target, or to… 
2003
2003
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.
Highly Cited
2002
Highly Cited
2002
Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo
Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an… 
Highly Cited
2001
Highly Cited
2001
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
The epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases have been implicated in the development, progression, and… 
Highly Cited
2001
Highly Cited
2001
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
Ductal carcinoma in situ (DCIS) expresses c‐erbB‐2 receptor and epidermal growth factor receptor (EGFR). The aim of this study… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)